| High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic … N Cruz-Rodriguez, AL Combita, LJ Enciso, SM Quijano, PL Pinzon, ... Journal of Experimental & Clinical Cancer Research 35, 1-14, 2016 | 32 | 2016 |
| Increased expression of deleted in malignant brain tumors (DMBT1) gene in precancerous gastric lesions: Findings from human and animal studies J Garay, MB Piazuelo, L Lopez-Carrillo, YA Leal, S Majumdar, L Li, ... Oncotarget 8 (29), 47076, 2017 | 22 | 2017 |
| Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia AG Kotini, S Carcamo, N Cruz-Rodriguez, M Olszewska, T Wang, ... Blood cancer discovery 4 (4), 318-335, 2023 | 18 | 2023 |
| Prognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL N Cruz-Rodriguez, AL Combita, LJ Enciso, LF Raney, PL Pinzon, ... Journal of Experimental & Clinical Cancer Research 36, 1-12, 2017 | 18 | 2017 |
| Epigenetics in hematological malignancies N Cruz-Rodriguez, AL Combita, J Zabaleta Cancer Epigenetics for Precision Medicine: Methods and Protocols, 87-101, 2018 | 17 | 2018 |
| Terapia génica para el tratamiento del cáncer JA Rodriguez, LM Martinez, N Cruz, AL Cómbita Revista Colombiana de Cancerología 18 (1), 27-40, 2014 | 17 | 2014 |
| Antitumor mechanisms of metformin: Signaling, metabolism, immunity and beyond JE Duque, C López, N Cruz Universitas Scientiarum 15 (2), 122-129, 2010 | 14 | 2010 |
| Establishment of two dimensional (2D) and three-dimensional (3D) melanoma primary cultures as a tool for in vitro drug resistance studies N Cruz Rodríguez, J Lineros, CS Rodríguez, LM Martínez, JA Rodríguez Immune Checkpoint Blockade: Methods and Protocols, 119-131, 2019 | 10 | 2019 |
| RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax J Sango, S Carcamo, M Sirenko, A Maiti, H Mansour, G Ulukaya, ... Nature, 1-10, 2024 | 7 | 2024 |
| Mecanismos moleculares emergentes y células madre leucémicas en la quimiorresistencia de tumores hematológicos LA Rey-Caro, P Pinzón, N Cruz-Rodríguez Revista de la Universidad Industrial de Santander. Salud 52 (2), 131-146, 2020 | 5 | 2020 |
| Novel treatment strategies for chronic myeloid leukemia N Cruz-Rodriguez, MW Deininger Blood Journal, blood. 2024026312, 2024 | 2 | 2024 |
| BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias? N Cruz-Rodriguez, H Tang, B Bateman, W Tang, M Deininger Leukemia 38 (9), 1885-1893, 2024 | 2 | 2024 |
| MIR4435-2HG as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL Y Torres-Llanos, J Zabaleta, N Cruz-Rodriguez, S Quijano, PC Guzmán, ... Frontiers in Molecular Biosciences 11, 1385140, 2024 | 2 | 2024 |
| Plant-derived extracts and metabolic modulation in leukemia: a promising approach to overcome treatment resistance CM Arévalo, N Cruz-Rodriguez, S Quijano, S Fiorentino Frontiers in Molecular Biosciences 10, 1229760, 2023 | 2 | 2023 |
| Abstract B69: Aggressiveness and tumor biology in prostate cancer patients with and without biochemical recurrence N Acosta, J Zabaleta, R Varela, J Mesa, S Serrano, J Garay, M Baddoo, ... Cancer Epidemiology, Biomarkers & Prevention 27 (7_Supplement), B69-B69, 2018 | 2 | 2018 |
| N/KRAS-Mutant AML lSCs originate from committed myelomonocytic progenitors and drive clinical resistance to venetoclax J Sango, S Carcamo, N Cruz-Rodriguez, M Sirenko, A Maiti, M Olszewska, ... Blood 142, 403, 2023 | 1 | 2023 |
| ID1 gene overexpression confers quiescence and chemoresistance in a leukemia cellular model JLP Agudelo, DFR Reyes, KLP Meza, AIP Da Silva, CEM Cristancho, ... Gene Reports 38, 102110, 2025 | | 2025 |
| ID1 and ID3 functions in the modulation of the tumour immune microenvironment in adult patients with B-cell acute lymphoblastic leukaemia N Poveda-Garavito, CA Orozco Castaño, Y Torres-Llanos, ... Frontiers in Immunology 15, 1473909, 2024 | | 2024 |
| Targeting Chronic Myeloid Leukemia with Potent and Specific BCR:: ABL1 Degraders N Cruz-Rodriguez, H Tang, M Rouhimoghadam, J Liao, B Bateman, ... Blood 144, 4157, 2024 | | 2024 |
| Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy X Huang, AD Pomicter, J Ahmann, Y Qiao, OS Chen, TI George, ... Blood Cancer Journal 14 (1), 179, 2024 | | 2024 |
